General Protocols for Stem Cell Therapies

Stem cell protocols in general encompass standardized steps for hematopoietic stem cell transplantation (HSCT) and mesenchymal stem cell (MSC) therapies, tailored to conditions like blood disorders or tissue regeneration. These involve patient evaluation, cell sourcing (autologous or allogeneic), conditioning, administration, and monitoring, with over 27 approved products worldwide emphasizing safety and regulatory compliance. Procedures prioritize minimal manipulation for homologous use where possible, but advanced therapies require rigorous quality control.

Pre-Treatment Evaluation

Patients undergo blood tests (CBC, infectious screening like HIV/hepatitis), cardiac assessments (EKG/echocardiogram), and organ function checks for liver, kidney, and lungs to confirm eligibility and determine dosing. Contraindications include active infections, severe anemia, or bone marrow cancers, with doctors assessing overall health and disease stage.

Cell Sourcing and Preparation

HSCs are collected via bone marrow harvest, peripheral blood apheresis after G-CSF mobilization, or cord blood; MSCs from bone marrow, adipose, or umbilical cord. Cells are purified, expanded if needed (e.g., 3-4 weeks for autologous MSCs), cryopreserved, and tested for viability, sterility, and potency before use. Doses range from 2-92 million cells/kg for HSCs and 50-150 million total for MSCs, depending on product and indication.

Conditioning and Administration

HSCT uses myeloablative or reduced-intensity conditioning (chemotherapy/radiation) to clear diseased cells and enable engraftment. Common routes include intravenous infusion (most frequent for systemic effects), intra-articular for joints, intrathecal for CNS, or local injections; no more than two administrations daily. Vital signs are monitored during procedures in GMP-grade facilities.

Post-Treatment Monitoring

Engraftment is tracked via blood counts, with risks like GvHD managed by immunosuppression; MSCs show low rejection due to immunomodulation. Recovery takes days to weeks, with improvements in 3-6 months; follow-up includes repeat dosing if needed and holistic therapies like physiotherapy. Allogeneic HSCTs report to databases like CIBMTR for outcomes.